Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization - Experimental study in a canine model of cardiopulmonary arrest

Circulation Journal

Volumn 70, Issue 9, 2006, Pages 1200-1207

  Yoshioka, Koichiro ^a   Amino, Mari ^a   Usui, Kazutane ^a   Sugimoto, Atsuhiko ^a   Matsuzaki, Atsushi ^a   Kohzuma, Kumiko ^a   Kanda, Shigetaka ^a   Deguchi, Yoshiaki ^a   Ikari, Yuji ^a   Kodama, Itsuo ^b   Tanabe, Teruhisa ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Activation recovery interval; Cardiopulmonary resuscitation; Nifekalant hydrochloride; QT interval; Transmural dispersion of repolarization

Indexed keywords

NIFEKALANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOPULMONARY ARREST; CONTROLLED STUDY; DOG; DRUG MECHANISM; ELECTROCARDIOGRAM; ENDOCARDIUM; EPICARDIUM; HEART INFARCTION; HEART LEFT VENTRICLE; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; NONHUMAN; QT INTERVAL; QT PROLONGATION; RESUSCITATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOPULMONARY RESUSCITATION; DISEASE MODELS, ANIMAL; DOGS; HEART ARREST; HEART CONDUCTION SYSTEM; HUMANS; PYRIMIDINONES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 33748669078     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.1200     Document Type: Article

References (23)

1. Nakaya H, Tohse N, Taakeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109: 157-163.
2. Hashimoto K, Haruo A, Hirasawa A, Awaji T, Xue YX, Wu ZJ. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias. Jpn J Pharmacol 1995; 68: 1-9.
3. Tanabe T, Iwamoto T, Iwata O, Aikawa M, Kusuzaki S, Handa S, et al. Electrophysiologic and blood-flow responses in the endocardium andepicardium to disopyramide and MS-551 during myocardial ischemia in the dog. J Cardiovasc Pharmacol 1999; 34: 275-286.
4. Amino M, Yamazaki M, Nakagawa H, Honjo H, Yoshioka K, Tanabe T, et al. Combined effects of nifekalant and lidocaine on the spiral-type reentry in a perfused 2-dimensional layer of rabbit ventricular myocardium. Circ J 2005; 69: 576-584.
5. Amino M, Yoshioka K, Tanabe T, Morita S, Nakagawa Y, Yamamoto I, et al. Efficacy of nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance of lidocaine: A study on the patients with out-of-hospital cardiac arrest. J Cardiol 2003; 41: 127-134.
6. Yoshioka K, Amino M, Usui K, Inokuchi S, Ikari Y, Kodama I, et al. Is nifekalant hydrochloride capable of being used as a first-line drug in cardiopulmonary resuscitation? Comparative study between out-of-hospital CPA with acidosis and in-hospital CPA without acidosis conditions. Circ J 2006; 70: 21-27.
7. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58: 107-115.
8. Hamlin RL, Kijtawornrat A, Keene BW. How many cardiac cycles must be measured to permit accurate RR, QT, and QTc estimates in conscious dogs? J Pharmacol Toxicol Methods 2004; 50: 103-108.
9. Tattersall ML, Dymond M, Hammond T, Valentin JP. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. J Pharmacol Toxicol Methods 2006; 53: 11-19.
10. Yoshioka K, Gao D-W, Chin M, Stillson C, Penades E, Lesh M, et al. Heterogeneous sympathetic innervation influences local myocardial repolarization in normally perfused rabbit hearts. Circulation 2000; 101: 1060-1066.
11. Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004; 110: 3661-3666.
12. Takenaka K, Yasuda S, Miyazaki S, Kurita T, Sutani Y, Morii I, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65: 60-62.
13. Koizumi T, Komiyama N, Komuro I, Tanigawa T, Iwase T, Ishiwata S, et al. Efficacy of nifekalant hydrochloraide on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction. Cardiovasc Drugs Ther 2001; 15: 363-365.
14. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: Post-marketing special investigation. Circ J 2005; 69: 1237-1243.
15. Grant AO, Strauss LJ, Wallace AG. The influence of pH on the electrophysiological effects of lidocaine in guinea pig ventricular myocardium. Circ Res 1980; 47: 542-550.
16. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J. The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 2005; 10: 67-76.
17. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23: 674-680.
18. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electricaldefibrillation eficacy during ventricular fibrillation? J Am Coll Cardiol 1997; 29: 688-692.
19. Sicouri S, Moro S, Litovsky S, Elizari MV, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysio 1997; 8: 1269-1279.
20. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-910.
21. Kodama I, Suzuki R, Toyama J. Sympathetic beta-adrenoceptor stimulation in cardiac muscle treated with class-III antiarrhythmic agents. Environ Med 1995; 39: 65-68.
22. Xue Y, Yamada C, Aye NN, Hashimoto K. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Br J Pharmacol 1998; 124: 1712-1718.
23. Modest VE, Butterworth JF 4th. Effect of pH and lidocaine on beta-adrenergic receptor binding: Interaction during resuscitation? Chest 1995; 108: 1373-1379.